Title : KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells.

Pub. Date : 2009 Jul 20

PMID : 19619321






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 CONCLUSION: Administration of Paclitaxel to patients with high percentage Type I cancer cells could have detrimental effects due to Paclitaxel-induced enhancement of NF-kappaB and ERK activities, and cytokine production (e.g. IL-6), which promote chemoresistance and tumor progression. Paclitaxel mitogen-activated protein kinase 1 Homo sapiens
2 CONCLUSION: Administration of Paclitaxel to patients with high percentage Type I cancer cells could have detrimental effects due to Paclitaxel-induced enhancement of NF-kappaB and ERK activities, and cytokine production (e.g. IL-6), which promote chemoresistance and tumor progression. Paclitaxel mitogen-activated protein kinase 1 Homo sapiens